ArticleMedComm2023

A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma.

Houyu Ju et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.